Literature DB >> 17917240

In vitro activity of novel rifamycins against gram-positive clinical isolates.

Christopher K Murphy1, Elena Karginova, Dan Sahm, David M Rothstein.   

Abstract

We describe novel rifamycins that have improved activity, compared with rifampin, against clinical isolates of staphylococci and streptococci, with MIC(90)s of 0.008 and 0.0005 microg/ml, respectively. This enhanced antibacterial activity, along with their potential lack of drug-drug interactions, are considerations that suggest the potential of these novel rifamycins in combination therapy to treat serious Gram-positive infections.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17917240     DOI： 10.1038/ja.2007.72

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN： 0021-8820            Impact factor:   2.649


  3 in total

1.  Population pharmacokinetics of rifampicin in adult patients with osteoarticular infections: interaction with fusidic acid.

Authors:  Amélie Marsot; Amelie Ménard; Julien Dupouey; Cedric Muziotti; Romain Guilhaumou; Olivier Blin
Journal:  Br J Clin Pharmacol       Date:  2017-01-16       Impact factor: 4.335

2.  Rifamycin antibiotic resistance by ADP-ribosylation: Structure and diversity of Arr.

Authors:  Jennifer Baysarowich; Kalinka Koteva; Donald W Hughes; Linda Ejim; Emma Griffiths; Kun Zhang; Murray Junop; Gerard D Wright
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-18       Impact factor: 11.205

3.  Evaluation of current dosing guidance for oral rifampicin treatment in adult patients with osteoarticular infections.

Authors:  Amélie Marsot; Amélie Ménard; Julien Dupouey; Laurent Allanioux; Olivier Blin; Romain Guilhaumou
Journal:  Br J Clin Pharmacol       Date:  2020-05-13       Impact factor: 4.335
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.